A
Adial Pharmaceuticals, Inc. (ADIL)
NCM – Real Time Price. Currency in USD
1.64
-0.08 (-4.65%)
At close: Mar 27, 2026, 4:00 PM EDT
1.75
+0.11 (6.79%)
After-hours: Mar 27, 2026, 7:39 PM EDT
Get all premium features to the best stock analysis tool
NCM – Real Time Price. Currency in USD
1.64
-0.08 (-4.65%)
At close: Mar 27, 2026, 4:00 PM EDT
1.75
+0.11 (6.79%)
After-hours: Mar 27, 2026, 7:39 PM EDT
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company’s lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Glen Allen, Virginia.
| Name | Position |
|---|---|
| Dr. Brigitte Robertson M.D. | Acting Chief Medical Officer |
| Mr. Abel Svitavsky CPA | Controller |
| Mr. Andrew Taubman | Vice President of Corporate Development |
| Mr. Cary John Claiborne MBA | CEO, President & Director |
| Mr. John R. Martin J.D. | Chief Legal Officer |
| Mr. Tony Goodman | COO & Director |
| Mr. Vinay Shah A.C.A., C.P.A., M.B.A. | CFO & Treasurer |
| Date | Type | Document |
|---|---|---|
| 2026-03-06 | 8-K | ea0280282-8k_adial.htm |
| 2026-03-05 | 10-K | ea0279150-10k_adial.htm |
| 2026-03-03 | 8-K | ea0279472-8k_adial.htm |
| 2026-01-06 | 8-K | ea027192401-8k_adialpharma.htm |
| 2025-12-23 | PRE 14A | ea0270782-pre14a_adialpharma.htm |
| 2025-12-12 | S-3 | ea0269270-s3_adial.htm |
| 2025-12-03 | D | |
| 2025-12-01 | 8-K | ea0267799-8k_adial.htm |
| 2025-11-14 | 8-K | ea0265418-8k_adial.htm |
| 2025-11-13 | 10-Q | ea0263114-10q_adial.htm |